145 related articles for article (PubMed ID: 2149504)
1. Clinical development of aromatase inhibitors for the treatment of breast and prostate cancer.
Dowsett M
J Steroid Biochem Mol Biol; 1990 Dec; 37(6):1037-41. PubMed ID: 2149504
[TBL] [Abstract][Full Text] [Related]
2. Aromatase inhibitors: clinical pharmacology and therapeutic implications in breast cancer.
Pérez N; Borja J
J Int Med Res; 1992 Aug; 20(4):303-12. PubMed ID: 1387368
[TBL] [Abstract][Full Text] [Related]
3. Endocrine, pharmacokinetic and clinical studies of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione ('pyridoglutethimide') in postmenopausal breast cancer patients.
Dowsett M; MacNeill F; Mehta A; Newton C; Haynes B; Jones A; Jarman M; Lonning P; Powles TJ; Coombes RC
Br J Cancer; 1991 Nov; 64(5):887-94. PubMed ID: 1931611
[TBL] [Abstract][Full Text] [Related]
4. Recent progress in development of aromatase inhibitors.
Santen RJ
J Steroid Biochem Mol Biol; 1990 Dec; 37(6):1029-35. PubMed ID: 2149503
[TBL] [Abstract][Full Text] [Related]
5. Postmenopausal estrogen synthesis and metabolism: alterations caused by aromatase inhibitors used for the treatment of breast cancer.
Lønning PE; Dowsett M; Powles TJ
J Steroid Biochem; 1990 Mar; 35(3-4):355-66. PubMed ID: 2139151
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of the actions of aromatase inhibitors 4-hydroxyandrostenedione, fadrozole, and aminoglutethimide on aromatase in JEG-3 cell culture.
Yue W; Brodie AM
J Steroid Biochem Mol Biol; 1997; 63(4-6):317-28. PubMed ID: 9459198
[TBL] [Abstract][Full Text] [Related]
7. Combined treatment with 4-hydroxyandrostenedione and aminoglutethimide: effects on aromatase inhibition and oestrogen suppression.
MacNeill FA; Jacobs S; Lønning PE; Powles TJ; Dowsett M
Br J Cancer; 1994 Jun; 69(6):1171-5. PubMed ID: 8198987
[TBL] [Abstract][Full Text] [Related]
8. Clinical use of aromatase inhibitors in human breast carcinoma.
Santen RJ
J Steroid Biochem Mol Biol; 1991; 40(1-3):247-53. PubMed ID: 1835644
[TBL] [Abstract][Full Text] [Related]
9. Aromatase and other inhibitors in breast and prostatic cancer.
Brodie AM; Banks PK; Inkster SE; Son C; Koos RD
J Steroid Biochem Mol Biol; 1990 Dec; 37(6):1043-8. PubMed ID: 2285580
[TBL] [Abstract][Full Text] [Related]
10. An in vitro method to determine the selective inhibition of estrogen biosynthesis by aromatase inhibitors.
Häusler A; Schenkel L; Krähenbühl C; Monnet G; Bhatnagar AS
J Steroid Biochem; 1989 Jul; 33(1):125-31. PubMed ID: 2527324
[TBL] [Abstract][Full Text] [Related]
11. Aromatase inhibition with 4-OHAndrostenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer.
Murray R; Pitt P
Breast Cancer Res Treat; 1995 Sep; 35(3):249-53. PubMed ID: 7579495
[TBL] [Abstract][Full Text] [Related]
12. Aromatization inhibition alone or in combination with GnRH agonists for the treatment of premenopausal breast cancer patients.
Dowsett M; Stein RC; Coombes RC
J Steroid Biochem Mol Biol; 1992 Sep; 43(1-3):155-9. PubMed ID: 1388047
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of aromatase with CGS 16949A in postmenopausal women.
Santen RJ; Demers LM; Adlercreutz H; Harvey H; Santner S; Sanders S; Lipton A
J Clin Endocrinol Metab; 1989 Jan; 68(1):99-106. PubMed ID: 2521224
[TBL] [Abstract][Full Text] [Related]
14. Aromatase, its inhibitors and their use in breast cancer treatment.
Brodie AM
Pharmacol Ther; 1993 Dec; 60(3):501-15. PubMed ID: 8073072
[TBL] [Abstract][Full Text] [Related]
15. Potency and selectivity of the non-steroidal aromatase inhibitor CGS 16949A in postmenopausal breast cancer patients.
Dowsett M; Stein RC; Mehta A; Coombes RC
Clin Endocrinol (Oxf); 1990 May; 32(5):623-34. PubMed ID: 2142026
[TBL] [Abstract][Full Text] [Related]
16. Formestane. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of breast cancer and prostatic cancer.
Wiseman LR; McTavish D
Drugs; 1993 Jan; 45(1):66-84. PubMed ID: 7680986
[TBL] [Abstract][Full Text] [Related]
17. The effect of the aromatase inhibitor, rogletimide (pyridoglutethimide), on guinea pig adrenal cell steroidogenesis and placental microsomal aromatase activity: comparison with aminoglutethimide and CGS 16949A.
Newton CJ; Mehta A; Dowsett M
J Steroid Biochem Mol Biol; 1991 Nov; 39(5A):723-7. PubMed ID: 1659868
[TBL] [Abstract][Full Text] [Related]
18. Second generation aromatase inhibitor--4-hydroxyandrostenedione.
Dowsett M; Coombes RC
Breast Cancer Res Treat; 1994; 30(1):81-7. PubMed ID: 7949207
[TBL] [Abstract][Full Text] [Related]
19. The effects of oral 4-hydroxyandrostenedione on peripheral aromatisation in post-menopausal breast cancer patients.
MacNeill FA; Jacobs S; Dowsett M; Lonning PE; Powles TJ
Cancer Chemother Pharmacol; 1995; 36(3):249-54. PubMed ID: 7781147
[TBL] [Abstract][Full Text] [Related]
20. Influence of aminoglutethimide on plasma oestrogen levels in breast cancer patients on 4-hydroxyandrostenedione treatment.
Lønning PE; Dowsett M; Jones A; Ekse D; Jacobs S; McNeil F; Johannessen DC; Powles TJ
Breast Cancer Res Treat; 1992; 23(1-2):57-62. PubMed ID: 1446052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
